within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX23_Desvenlafaxine;

model Desvenlafaxine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 3.055555555555555e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0034,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 9.6);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Desvenlafaxine</td></tr><tr><td>ATC code:</td><td>N06AX23</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used in the treatment of major depressive disorder (MDD) in adults. It is approved by the FDA and marketed under the brand name Pristiq.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration of a 100 mg tablet.</p><h4>References</h4><ol><li><p>Nichols, AI, et al., &amp; Abbas, R (2018). Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. <i>Clinical pharmacology in drug development</i> 7(4) 441–450. DOI:<a href=\"https://doi.org/10.1002/cpdd.419\">10.1002/cpdd.419</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29228473/\">https://pubmed.ncbi.nlm.nih.gov/29228473</a></p></li><li><p>Dolder, C, et al., &amp; Stump, A (2010). Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. <i>Drugs &amp; aging</i> 27(8) 625–640. DOI:<a href=\"https://doi.org/10.2165/11537140-000000000-00000\">10.2165/11537140-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20658791/\">https://pubmed.ncbi.nlm.nih.gov/20658791</a></p></li><li><p>Chen, YX, et al., &amp; Zhong, DF (2015). [The enantioselective pharmacokinetic study of desvenlafaxine sustained release tablet in Chinese healthy male volunteers after oral administration]. <i>Yao xue xue bao = Acta pharmaceutica Sinica</i> 50(4) 486–491. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26223133/\">https://pubmed.ncbi.nlm.nih.gov/26223133</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX23 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Desvenlafaxine;
